论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Qiao YH, Zhu BL, Tian AJ, Li ZJ
Received 22 December 2016
Accepted for publication 16 May 2017
Published 3 July 2017 Volume 2017:12 Pages 4709—4719
DOI https://doi.org/10.2147/IJN.S130951
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jiang Yang
Peer reviewer comments 4
Editor who approved publication: Dr Lei Yang
Abstract: Gold nanoparticles (AuNPs) are widely used as a drug delivery
vehicle, which can accumulate in the heart through blood circulation.
Therefore, it is very important to understand the effect of AuNPs on the heart,
especially under pathological conditions. In this study, we found that
PEG-coated AuNPs attenuate β-adrenergic receptor (β-AR)-mediated acute cardiac
hypertrophy and inflammation. However, both isoproterenol, a non-selective β-AR
agonist, and AuNPs did not induce cardiac function change or cardiac fibrosis.
AuNPs exerted an anti-cardiac hypertrophy effect by decreasing β1-AR expression and its downstream ERK1/2
hypertrophic pathway. Our results indicated that AuNPs might be safe and have
the potential to be used as multi-functional materials (drug carrier systems
and anti-cardiac hypertrophy agents).
Keywords: AuNPs, cardiac
hypertrophy, β-adrenergic receptor, ERK1/2 signaling pathway